What medication options are appropriate for an adult with generalized anxiety disorder without contraindicating medical conditions?

Medication for Anxiety in Adults

For generalized anxiety disorder in adults, start with SSRIs (specifically escitalopram or sertraline) or the SNRI venlafaxine as first-line pharmacotherapy, based on the most recent evidence showing superior efficacy and acceptable tolerability. 1, 2

First-Line Pharmacotherapy

The 2023 Japanese Society guidelines and recent network meta-analyses consistently identify SSRIs and SNRIs as the primary pharmacological options 1, 2, 3:

Preferred Initial Agents:

• Escitalopram: Demonstrated the strongest efficacy in network meta-analysis with a weighted mean difference of -3.2 on the Hamilton Anxiety Scale, significantly better than placebo 2
• Duloxetine: Showed superior efficacy alongside escitalopram in comparative studies 2
• Sertraline: Recommended particularly for older adults due to favorable side effect profile 4
• Venlafaxine (SNRI): Suggested as equivalent first-line option to SSRIs 1

Key Prescribing Considerations:

• SSRIs and SNRIs require 4-6 weeks for full therapeutic effect
• Start at lower doses and titrate based on response and tolerability
• These agents have acceptable long-term safety profiles without significant adverse effects with chronic use 3
• Sexual side effects are common with SSRIs/SNRIs

Second-Line Options

If first-line SSRIs/SNRIs are ineffective or not tolerated 4:

• Switch to alternative SSRI or SNRI (different mechanism may help)
• Pregabalin/Gabapentin: Evidence supports efficacy, particularly pregabalin 5, 6, 4
• Buspirone: Reasonable option when avoiding sexual side effects is priority, though requires relatively healthy patients 4

Third-Line Considerations

For treatment-resistant cases 4:

• Quetiapine: Atypical antipsychotic with evidence for GAD, but reserve for inadequate response to multiple trials due to metabolic side effects 7, 5
• Mirtazapine: Mixed antidepressant with some supportive evidence 6, 4

Critical Warnings - What NOT to Use

Benzodiazepines are NOT recommended for first-line therapy or long-term use despite their rapid anxiolytic effects 8, 3:

• Risk of dependence and withdrawal
• Cognitive impairment, especially in older adults
• Increased mortality risk
• Falls risk in elderly
• Only consider for short-term bridging while awaiting SSRI/SNRI effect, then taper

Avoid in routine practice:

• Antihistamines (hydroxyzine) - limited efficacy data 6, 4
• Over-the-counter "sleep aids" - lack efficacy and safety data 9
• Barbiturates - not recommended 9

Treatment Algorithm

Step 1: Initiate escitalopram 10mg daily OR sertraline 50mg daily OR duloxetine 30mg daily

• Titrate after 1-2 weeks if tolerated
• Assess response at 4-6 weeks

Step 2 (if inadequate response): Switch to alternative SSRI/SNRI not yet tried

• Full trial = 8-12 weeks at therapeutic dose

Step 3 (if still inadequate): Add or switch to:

• Pregabalin 150-600mg daily, OR
• Buspirone 15-30mg daily (divided doses)

Step 4 (treatment-resistant): Consider quetiapine 50-300mg daily

• Monitor metabolic parameters closely

Special Populations

Older Adults (≥65 years):

• Prefer sertraline or escitalopram due to fewer drug interactions 4
• Avoid benzodiazepines due to falls risk and cognitive effects
• Start at half the usual adult dose
• Exercise particular caution with medications causing sedation or orthostasis

Patients with comorbid depression:

• SSRIs/SNRIs treat both conditions simultaneously 9
• Duloxetine particularly effective for comorbid pain syndromes

Common Pitfalls to Avoid

1. Premature discontinuation: Patients may stop SSRIs/SNRIs before 4-6 weeks, missing therapeutic window
2. Inadequate dosing: Underdosing is common; ensure therapeutic doses are reached
3. Benzodiazepine dependence: Easy to start, difficult to stop - avoid routine use
4. Ignoring psychotherapy: Cognitive behavioral therapy is equally effective and should be offered alongside or instead of medication 1, 3
5. Polypharmacy without systematic trials: Complete adequate trials of monotherapy before combining agents

Duration of Treatment

• Continue effective medication for at least 12 months after symptom remission
• Taper gradually when discontinuing to avoid withdrawal symptoms
• Many patients require long-term maintenance therapy 9

The evidence strongly supports SSRIs/SNRIs as foundational pharmacotherapy, with escitalopram and duloxetine showing the most robust efficacy data in recent meta-analyses 2. Benzodiazepines should be actively avoided despite their historical use, given clear evidence of harm with long-term administration 8, 3.